Third Party Acquirer. OV shall have the right to identify and secure a Third Party to acquire (via sale, license, merger or otherwise) and assume the rights to the DRP Biomarker. Any agreement with such a Third Party to the DRP Biomarker shall be at the sole discretion ofOV, with advance written notice to R-Pharm.
Appears in 2 contracts
Sources: Development, Option and License Agreement (Allarity Therapeutics, Inc.), Development, Option and License Agreement (Allarity Therapeutics, Inc.)